Phaseline

Companies › LaNova Medicines Zhejiang

LaNova Medicines Zhejiang: clinical trials, targets and expected readouts

1 active drug program in 2 registered trials: 1 Phase 3, 1 Phase 2; Oncology; next expected readout Nov 2026.

Open in Phaseline: competitors, likelihood bands and readouts Company report

Programs

DrugTargetHighest phaseConditionsNext expected readout
LM-302
anti-CLDN18.2 antibody-drug conjugate
CLDN18Phase 3Locally Advanced or Metastatic GC and GCJ Adenocarcinoma; Malignant Neoplasms of Digestive OrgansNov 2026

Trials

Registry idDrugPhaseConditionsAreaExpected readout
NCT06351020LM-302Phase 3Locally Advanced or Metastatic GC and GCJ AdenocarcinomaOncologyNov 2026
NCT05934331LM-302Phase 2Malignant Neoplasms of Digestive OrgansOncologyAug 2031

Targets

CLDN18 (1)

Companies with the same targets

Astellas AstraZeneca RemeGen Shanghai Institute Of Biological Products Beijing Biotech Sichuan Kelun-Biotech Biopharmaceutical Biokin (Shanghai) Biopharmaceutical Transcenta Therapeutics (Hangzhou) Shanghai Hengrui Pharmaceutical Innovent Biologics (Suzhou)

Companies built like this

Biokin (Shanghai) Biopharmaceutical Hangzhou Sumgen Biotech Suzhou Immunofoco Biotechnology FutureGen Biopharmaceutical (Beijing) NingBo Junyan Hongshi Biosciences

Pipelines of the same shape: areas, drug types, target families, stage and cash runway.

Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.